MASTERMIND-Pneumonia Study (Also Known as Pneumonia Direct Pilot)
Completed · NCT06181669
Conditions: Pneumonia, Bacterial, Ventilator Associated Pneumonia
At a glance
- Research payments reported, 2025
- $1,174
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 173
About the trial
- Sponsor
- Duke University (with National Institute of Allergy and Infectious Diseases (NIAID))
- Tested
- Pathogen and Host Directed testing (diagnostic_test)
- Dates
- Started 2024-04-12; completion 2025-07-03
- Results posted
- Not yet
The MASTERMIND-Pneumonia Study (also known as Pneumonia Direct Pilot Study) is designed to assess whether combining molecular diagnostics for bacteria and AMR markers with host-response profiling improves agreement and predictive value for the diagnosis of VAP versus an adjudicated clinical reference standard. The feasibility design is intended to inform future interventional studies that will investigate the clinical impact of combined pathogen- and host-directed testing approaches.
From ClinicalTrials.gov, last updated 2026-04-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Biofire Diagnostics, LLC reported $1,174 in research payments for this study in 2025 (1 payments).
Products named: Filmarray Pneumonia PAnel (pneumo)
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.